ABT vs SHC
ABT: Abbott Laboratories is a diversified healthcare giant providing a broad portfolio of diagnostic systems, medical devices, nutritional products, and established branded generic pharmaceuticals. SHC: A global sterilization and lab testing partner ensuring the safety of medical devices and pharmaceuticals for 40+ top-50 device makers and 9 of top-10 pharma companies.
Side-by-side fundamentals
| Metric | ABT | SHC | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $100.75 | $17.49 | |
| Market cap as of 2026-07-24 | $175.7B | $4.9B | |
| P/E as of 2026-07-24 | 32.39 | 42.00 | ABT lower |
| PEG as of 2026-07-24 | 2.66 | 3.82 | ABT lower |
| Net margin as of 2026-07-24 | +11.7% | +9.9% | ABT higher |
| Gross margin as of 2026-07-24 | +56.8% | +55.3% | ABT higher |
| Operating margin as of 2026-07-24 | +15.8% | +29.0% | SHC higher |
| ROE as of 2026-07-24 | +12.2% | +20.6% | SHC higher |
| ROA as of 2026-07-24 | +6.9% | +3.6% | ABT higher |
| Debt / equity as of 2026-07-24 | 0.65 | 3.59 | ABT lower |
| Revenue growth (YoY) as of 2026-07-24 | +8.1% | +7.4% | ABT higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +5.1% | SHC higher |
| Dividend yield as of 2026-07-24 | +2.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-07-24 | 0.57 | 1.78 | |
| 1-year return as of 2026-07-23 close | -20.0% | +47.6% | SHC higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.